Hydroxycarbamide

Hydroxycarbamide
Hydroxycarbamide
Structural formula
Systematic (IUPAC) name
hydroxyurea
Clinical data
Trade names Apo-Hydroxyurea, Droxia, Hydrea
AHFS/Drugs.com International Drug Names
MedlinePlus a682004
Pregnancy cat. D (USA)
Legal status  ?
Routes Oral
Pharmacokinetic data
Metabolism Liver
Half-life 3-4 hours
Excretion Renal and lungs
Identifiers
CAS number 127-07-1 YesY
ATC code L01XX05
PubChem CID 3657
DrugBank APRD00023
ChemSpider 3530 YesY
UNII X6Q56QN5QC YesY
KEGG D00341 YesY
ChEBI CHEBI:44423 YesY
ChEMBL CHEMBL467 YesY
Chemical data
Formula CH4N2O2 
Mol. mass 76.0547 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Hydroxycarbamide (INN) or hydroxyurea (brand names include Hydrea and Droxia) is an antineoplastic drug, first synthesized in 1869, used in myeloproliferative disorders, specifically polycythemia vera and essential thrombocythemia. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.

Contents

Mechanism of action

One mechanism of action is thought to be based on its reduction of production of deoxyribonucleotides[1] via inhibition of the enzyme ribonucleotide reductase by scavenging tyrosyl free radicals as they are involved in the reduction NDPs.[2]

In the treatment of sickle-cell disease, hydroxycarbamide increases the concentration of fetal hemoglobin. The precise mechanism of action is not yet clear, but it appears that hydroxycarbamide increases nitric oxide levels, causing soluble guanylyl cyclase activation with a resultant rise in cyclic GMP, and the activation of gammaglobin synthesis necessary for fetal hemoglobin (by removing the rapidly dividing cells that preferentially produce sickle hemoglobin).[2][3]

Uses

Hydroxycarbamide is used for the following indications:

Dose

The dose depends on the indication, but tends to be 500 milligrams once a day when treatment is initiated. In myeloproliferative disease, further increases are determined by the response of the cell count and whether myelosuppression (decreased production of other blood cells) develops.[citation needed]

In sickle-cell disease, the initial daily dose is 15 mg per kilogram body weight (or less in reduced kidney function); after two weeks, a fall in the hemoglobin and platelet count and an increase in MCV (mean corpuscular volume) (size of the red blood cells) is to be expected. The dose is then increased every two weeks with monitoring of the full blood count until the dose is either 35 mg/kg or cytopenias develop.[2]

Side effects

Reported side-effects are: drowsiness, nausea, vomiting and diarrhea, constipation, mucositis, anorexia, stomatitis, bone marrow toxicity (which may take 7–21 days to recover after the drug has been discontinued), alopecia (hair loss), skin changes, abnormal liver enzymes, creatinine and blood urea nitrogen.[9]

Due to its effect on the bone marrow, regular monitoring of the full blood count is vital, as well as early response to possible infections. In addition, renal function, uric acid and electrolytes, as well as liver enzymes, are commonly checked.[citation needed]

Hydroxycarbamide has been used primarily for the treatment of myeloproliferative diseases, which has an inherent risk of transforming to acute myeloid leukemia. There has been a longstanding concern that hydroxycarbamide itself carries a leukemia risk, but large studies have shown that the risk is either absent or very small. Nevertheless, it has been a barrier for its wider use in patients with sickle-cell disease.[2]

Contraindications

Contraindications are: severe anemia, neutropenia.[citation needed]

Use in pregnancy

Category D - investigational or post-marketing data show risk to the fetus. However, potential benefits may outweigh the potential risk. Generally this rating is reserved for drugs with no safer alternatives.[9]

Synthesis

Hydroxyurea was first synthesized in 1869 by Dresler and Stein from hydroxylamine and hydrogen cyanate; the industrial process is analogous.[10] Hydroxyurea may also be synthesized by reaction of ethyl carbamate with hydroxylamine; hydroxylamine displaces the ester to give the amide.[11]

References

  1. ^ "hydroxyurea" at Dorland's Medical Dictionary
  2. ^ a b c d Platt OS (2008). "Hydroxyurea for the treatment of sickle cell anemia". N. Engl. J. Med. 358 (13): 1362–9. doi:10.1056/NEJMct0708272. PMID 18367739. 
  3. ^ Cokic VP, Smith RD, Beleslin-Cokic BB, et al. (2003). "Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase". J Clin Invest 111 (2): 231–9. doi:10.1172/JCI16672. PMC 151872. PMID 12531879. http://www.jci.org/articles/view/16672.  Full text at PMC: 151872
  4. ^ Harrison CN, Campbell PJ, Buck G, et al. (July 2005). "Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia". N. Engl. J. Med. 353 (1): 33–45. doi:10.1056/NEJMoa043800. PMID 16000354. http://content.nejm.org/cgi/pmidlookup?view=short&pmid=16000354&promo=ONFLNS19. 
  5. ^ Lanzkron S, Strouse JJ, Wilson R, et al. (June 2008). "Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease". Ann. Intern. Med. 148 (12): 939–55. PMID 18458272. 
  6. ^ Frank I, Bosch RJ, Fiscus S, et al. (September 2004). "Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307". AIDS Res. Hum. Retroviruses 20 (9): 916–26. doi:10.1089/aid.2004.20.916. PMID 15597521. 
  7. ^ Sharma VK, Dutta B, Ramam M (2004). "Hydroxyurea as an alternative therapy for psoriasis". Indian J Dermatol Venereol Leprol 70 (1): 13–7. PMID 17642550. http://www.ijdvl.com/article.asp?issn=0378-6323;year=2004;volume=70;issue=1;spage=13;epage=17;aulast=Sharma. 
  8. ^ Koç A, Wheeler LJ, Mathews CK, Merrill GF (January 2004). "Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools". J. Biol. Chem. 279 (1): 223–30. doi:10.1074/jbc.M303952200. PMID 14573610. http://www.jbc.org/cgi/pmidlookup?view=long&pmid=14573610. 
  9. ^ a b Liebelt, E.; Balk, S.; Faber, W.; Fisher, J.; Hughes, C.; Lanzkron, S.; Lewis, K.; Marchetti, F. et al. (2007). "NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea". Birth defects research. Part B, Developmental and reproductive toxicology 80 (4): 259–366. doi:10.1002/bdrb.20123. PMID 17712860.  edit
  10. ^ Lunghi, A; Aloni, C; Gigante, L; Mazzei, N; Cardillo, P (2002). "Hydroxyurea explosion: a thermoanalytical and calorimetric study". Journal of Loss Prevention in the Process Industries 15 (6): 489–495. doi:10.1016/S0950-4230(02)00044-X. 
  11. ^ R. Deghenghi (1973), "Hydroxyurea", Org. Synth., http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?prep=cv5p0645 ; Coll. Vol. 5: 645 



Wikimedia Foundation. 2010.

Игры ⚽ Поможем сделать НИР

Look at other dictionaries:

  • hydroxycarbamide — SYN: hydroxyurea. * * * (hydroxyurea) n. a drug that prevents cell growth and is used to treat some types of leukaemia. It is administered by mouth. Hydroxycarbamide may lower the white cell content of the blood due to its effects on the bone… …   Medical dictionary

  • hydroxycarbamide — hydroxyurea; n. a drug that prevents cell growth and is used mainly to treat chronic myeloid leukaemia. It is administered by mouth. Hydroxycarbamide may lower the white cell content of the blood due to its effects on the bone marrow. Trade names …   The new mediacal dictionary

  • hydroxycarbamide — noun Hydroxyurea …   Wiktionary

  • Essential thrombocytosis — DiseaseDisorder infobox Name = Essential thrombocytosis ICD10 = ICD10|D|75|2|d|70, ICD10|D|47|3|d|37 ICD9 = ICD9|238.71 ICDO = 9962/3 Caption = OMIM = 187950 DiseasesDB = 4522 MedlinePlus = 000543 eMedicineSubj = med eMedicineTopic = 2266 MeshID …   Wikipedia

  • Myelofibrosis — Classification and external resources ICD 10 C94.5, D47.1 ICD 9 …   Wikipedia

  • Hydroxyurée — Structure chimique de l hydroxyurée, un carbamide. Général No CAS …   Wikipédia en Français

  • Гидроксикарбамид медак — Действующее вещество ›› Гидроксикарбамид* (Hydroxycarbamide*) Латинское название Hydroxycarbamide medac АТХ: ›› L01XX05 Гидроксикарбамид Фармакологическая группа: Антиметаболиты Состав и форма выпуска Капсулы1 капс.гидроксикарбамид500… …   Словарь медицинских препаратов

  • hydroxyurea — An oral antineoplastic agent that inhibits DNA synthesis; used in the treatment of a variety of malignancies including melanoma, chronic myelocytic leukemia, and carcinoma of the ovary. SYN: hydro …   Medical dictionary

  • Chemotherapy — A woman being treated with docetaxel chemotherapy for breast cancer. Cold mittens and wine coolers are placed on her hands and feet to reduce harm to her nails. Chemotherapy (sometimes cancer chemotherapy) is the treatment of cancer with an… …   Wikipedia

  • Urea — Urea …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”